Phase III Study of Hemospan® to Prevent Hypotension in Hip Arthroplasty

PHASE3CompletedINTERVENTIONAL
Enrollment

375

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

June 30, 2008

Conditions
HypotensionIschemia
Interventions
DRUG

Hemospan (MP4OX)

250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers

DRUG

Voluven (HES 130/0.4)

250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers

Trial Locations (18)

Unknown

Univ. Ziekenhuis Antwerp, Antwerp

Cliniques Universitaires Saint-Luc, Brussels

ZOL Campus Sint-Jan, Genk

AZ St. Lucas Hospital, Ghent

Fakultni nemocnice Hradec Kralove, Hradec Králové

Oblastni nemocnice Kladno, Kladno

Fakultni nemocnice Motol, Prague

Fakultni nemocnice Na Bulovce, Prague

Sint Maartenskliniek, Nijmegen

Universitair Medisch Centrum St. Radboud, Nijmegen

SPSK nr 4, Klinika Ortopedii, Traumatologii i Rehabilitacji AM, Lublin

SP Wojewódzki Szpital Chirurgii Urazowej, Piekary Śląskie

Wojewódzki Szpital Specjalistyczny nr 5, Sosnowiec

SK Dzieciątka Jezus, Warsaw

Skaraborg Hospital, Skövde

Karolinska Hospital, Stockholm

S:t Görans Hospital, Stockholm

Univ. Hospital - Queen's Medical Center, Nottingham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sangart

INDUSTRY